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Crosstalk exists in mammalian cells between choles-
terol trafficking and innate immune signaling. Apoli-
poprotein A-I (apoA-I), a serum apolipoprotein that
induces antiatherogenic efflux of macrophage
cholesterol, is widely described as anti-inflammatory
because it neutralizes bacterial lipopolysaccharide.
Conversely, lipopolysaccharide-induced inflamma-
tion is proatherogenic. However, whether innate im-
munity plays an endogenous, physiological role in
host cholesterol homeostasis in the absence of
infection is undetermined. We report that apoA-I
signals in the macrophage through Toll-like receptor
(TLR)2, TLR4, and CD14, utilizingmyeloid differentia-
tion primary response protein 88 (MyD88)-dependent
and -independent pathways, to activate nuclear
factor-kB and induce cytokines. MyD88 plays a
critical role in reverse cholesterol transport in vitro
and in vivo, in part through promoting ATP-binding
cassette A1 transporter upregulation. Taken to-
gether, this work identifies apoA-I as an endogenous
stimulus of innate immunity that couples cholesterol
trafficking to inflammation through MyD88 and
identifies innate immunity as a physiologic signal in
cholesterol homeostasis.
INTRODUCTION
In the mammalian plasma membrane, two-way crosstalk occurs
between endogenous cholesterol trafficking pathways and
innate immune responses to pathogens by Toll-like receptors
(TLRs). Bacterial lipopolysaccharide (LPS) activates signals in
macrophages by recruiting TLR4 and its intracellular adaptors,
such as myeloid differentiation primary response protein 88
(MyD88), to cholesterol-rich lipid raft membrane microdomains
(Triantafilou et al., 2002). The cholesterol content of membrane
rafts can itself regulate cellular signaling by determining theCselective localization of signaling proteins to these microdo-
mains (Foster et al., 2003). Indeed, pharmacologic or genetic
manipulation of membrane cholesterol may suffice to activate
TLRs (Sun et al., 2009). In turn, raft cholesterol content is
normally regulated by homeostatic traffic of cholesterol from
the plasma membrane to extracellular acceptors, such as
apolipoprotein A-I (apoA-I) in particular (Murphy et al., 2008).
Thus, apoA-I, a lipid-binding protein that induces cholesterol
export from the cell, is positioned as a pivotal regulator of innate
immunity.
ApoA-I, a 243 amino acid serum apolipoprotein, is proposed
to contribute to atheroprotection in part by promoting reverse
cholesterol transport (RCT), the process by which cholesterol
in macrophages and other cells is exported to apoA-I for trans-
port via the blood to bile and then feces. ApoA-I is moreover
widely considered anti-inflammatory in the context of LPS, an
activity likely due both to its binding/neutralization of LPS and
to its effect on raft lipid (Berbee et al., 2005). Conversely, LPS
inhibits RCT (McGillicuddy et al., 2009), and innate immunity is
conventionally considered proatherogenic (Bjorkbacka et al.,
2004b; Khovidhunkit et al., 2004; Michelsen et al., 2004). Recent
reports in the lung, however, indicate that innate immunity is not
restricted to exogenous microbial challenges but may also play
non-pathogen-related homeostatic roles by responding to
endogenous ligands (Zhang et al., 2006). As innate immunity is
generally considered a response to external insult, there has
been no investigation to date of whether it plays endogenous,
physiological roles in cholesterol trafficking in the absence of
infection.
Chemical extraction of membrane cholesterol into the extra-
cellular space by cyclodextrins (CDs) impairs subsequent cell
signaling responses to LPS by displacing raft lipid and protein
(Fessler et al., 2004). It is perhaps less well-recognized that
CDs themselves nonetheless acutely induce responses in leuko-
cytes through TLR4 and MyD88 (Fessler et al., 2004; Flemming
et al., 2004). This suggests that, though raft cholesterol is neces-
sary for TLR4 activation by LPS as a ligand, acute, primary fluxes
in membrane lipid may nevertheless be sufficient events to
trigger the protein-protein interactions of innate immunity.
ApoA-I exerts effects on plasma membrane lipid grossly similar
to those of CDs (Murphy et al., 2008) and, moreover, structurallyell Metabolism 11, 493–502, June 9, 2010 ª2010 Elsevier Inc. 493
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type I viral fusion protein family (Oda et al., 2003), members of
which stimulate TLR4 (Kurt-Jones et al., 2000). We thus
reasoned that apoA-I might also trigger TLR4-/MyD88-depen-
dent signals in the macrophage. Second, as apoA-I-elicited
intracellular signals regulate efflux of cellular cholesterol (Nofer
et al., 2003), we further hypothesized that MyD88 might then
regulate mobilization of cellular cholesterol to apoA-I. Herein,
we report that apoA-I indeed stimulates a proinflammatory
cascade to nuclear factor (NF)-kB-dependent cytokine induction
through TLR4 and TLR2 and their adaptors in the macrophage. In
addition, we demonstrate that MyD88 plays a crucial role in
apoA-I-dependent RCT in vitro and in vivo. Taken together, we
propose that innate immune signals mediated by MyD88 serve
as physiologic ‘‘second messengers’’ in the homeostatic, antia-
therogenic RCT pathway.
RESULTS
ApoA-I Activates MyD88-Dependent Signals
in Macrophages
Chemical extraction of cholesterol from the plasma membrane
of leukocytes with CDs induces an acute proinflammatory
signaling cascade that approximates TLR4 responses, likely
due to secondary translocation of proteins to/from membrane
microdomains (Fessler et al., 2004; Flemming et al., 2004).
MyD88 is an intracellular TLR adaptor that transduces an early
phase of mitogen-activated protein kinase (MAPK) and NF-kB
activation by LPS (O’Neill and Bowie, 2007). As previously
reported for B cells (Flemming et al., 2004), we confirmed in
macrophages that methyl-b-CD activates MAPKs and triggers
degradation of IkBa, an indicator of NF-kB activation (Schuster
and Nelson, 2000), through a MyD88-dependent mechanism
(Figure S1). ApoA-I, an apolipoprotein cholesterol acceptor,
similarly activated p38, c-Jun N-terminal kinase (JNK), and
NF-kB through MyD88 (Figure 1A, left). In Myd88/ macro-
phages, as compared to Myd88+/+, apoA-I-induced p38 activa-
tion and IkBa degradation were delayed, and JNK activation was
markedly attenuated, similar to LPS (Figure S2A). Human mono-
cyte-derived macrophages were similarly responsive to apoA-I
(Figure 1A, right). ApoA-I activated DNA binding of p65 NF-kB
in nuclear isolates of murine and human macrophages, and did
so through a MyD88-dependent mechanism in the former case
(Figure 1B).
Commercial serum-derived lipid-free apoA-I, which was
initially found to have 27 pg LPS contamination per microgram
of protein by Limulus test, was column repurified and found
thereafter to have undetectable levels of LPS (i.e., <0.06 EU
[<6 pg] per 10 mg apoA-I). The experiments in this report used
this repurified apoA-I under serum-free conditions, which are
devoid of LPS-binding protein. Though under these conditions
100 ng/ml LPS had minimal activity upon p38, JNK, and NF-kB
(Figure 1C), polymyxin B (PB, 25 mg/ml), an LPS-neutralizing
agent, was nevertheless used in all experiments in order to
address the possibility that apoA-I-bound LPS could escape
detection and elicit signals. Whereas LPS at 100 ng/ml (Fig-
ure 1C) and indeed at 2 mg/ml (data not shown), namely >3 3
105-fold higher than the Limulus detection threshold, was
neutralized by PB, apoA-I signaling was unaffected (Figure 1C).494 Cell Metabolism 11, 493–502, June 9, 2010 ª2010 Elsevier Inc.Unlike peptidoglycan (PGN) (Figure 1D) and LPS (Figure S2B),
which, as expected, were protease resistant, pretreatment of
apoA-I with protease ablated its signaling activity (Figure 1D).
Like apoA-I, apoE, another amphipathic a-helical apolipopro-
tein, also activated MAPKs and NF-kB in a MyD88-dependent
fashion (Figure 1E). By contrast, although apoA-I comprises
80% of high-density lipoprotein (HDL) protein (Lee et al.,
2004), HDL did not activate NF-kB, even at higher concentra-
tions than used for apoA-I; had minimal activity upon p38; and
activated JNK in a MyD88-independent fashion (Figure 1E).
PB abolished p38 activation by macrophages coexposed to
10 ng/ml LPS and 10 mg/ml HDL (data not shown), indicating
that apolipoproteins do not shelter LPS from PB neutralization
in our system.
ApoA-I has a complex lipid- and oxidation-sensitive se-
condary structure that impacts its function, and these modifica-
tions occur in vivo (Lagerstedt et al., 2007). To corroborate our
results with serum-isolated, delipidated apoA-I, we tested
bacterially expressed, column-repurified WT apoA-I (Lagerstedt
et al., 2007; Oda et al., 2003). Recombinant WT apoA-I activated
p38 and JNK in murine macrophages through a MyD88-depen-
dent mechanism (Figure 1F). Unlike LPS, this activity was unaf-
fected by PB. Serum-isolated, native apoA-I was used in all
experiments that follow except where specified.
In addition to MyD88, other adaptor proteins play important
roles in mediating signals from TLRs to the cell interior. Toll-inter-
leukin 1 receptor (TIR) domain-containing adaptor protein
(TIRAP) is a coadaptor with MyD88 for TLR2 and TLR4 signals,
bridging MyD88 to the intracellular domains of these two recep-
tors (O’Neill and Bowie, 2007). We thus questioned whether
TIRAP mediates the apoA-I signal. Tirap/ macrophages
indeed displayed similar attenuation of apoA-I-induced p38 and
IkBa signals as observed in Myd88/ macrophages (Figure 1G,
Figure S2C). Given the delayed signaling in Myd88/ cells (Fig-
ure 1A), we also queried whether an additional adaptor was
involved. TIR-domain-containing adaptor-inducing interferon-
b (TRIF), an adaptor commonly referred to as the MyD88-inde-
pendent pathway, transduces a late phase of LPS-induced
MAPK and NF-kB activation (O’Neill and Bowie, 2007). Trif/
macrophages indeed had attenuated activation of p38, JNK,
and NF-kB at late time points of apoA-I exposure (60 min for
p38/JNK, 75 min for p65 NF-kB) (Figure 1H), suggesting that
TRIF mediates a late phase of apoA-I signaling.
ApoA-I activates the Rho GTPase Cdc42 upstream of MAPKs
in fibroblasts (Argmann et al., 2005; Nofer et al., 2003). Rho
GTPases also regulate TLR2- and TLR4-dependent signaling
(Fessler et al., 2004). Testing the macrophage, we found that
Cdc42 and Rac are activated by apoA-I (Figure 1I). Pretreatment
of macrophages with C. difficile toxin B, which inhibits RhoA,
Cdc42, and Rac, attenuated apoA-I-induced activation of p38
and JNK but not IkBa degradation, whereas C3 transferase, a
selective RhoA inhibitor, had no effect (Figure 1J). Taken
together, these results suggest that Cdc42 or Rac lies upstream
of MAPK but not NF-kB activation in the apoA-I cascade, and
that the pathways to MAPK and NF-kB are distinct.
ApoA-I Signals through TLR2 and TLR4 in Macrophages
Given our findings that the TLR4 adaptors MyD88, TIRAP, and
TRIF regulate apoA-I signaling in the macrophage, we next
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Figure 1. ApoA-I Activates Macrophages through MyD88-Dependent and -Independent Pathways
(A) Peritoneal exudate macrophages (PEMs) from Myd88+/+ and Myd88/ mice were treated with apoA-I (10 mg/ml) (left [L]), and human monocyte-derived
macrophages were treated with apoA-I (50 mg/ml) (right [R]) for times indicated. Lysates were then immunoblotted for indicated targets.
(B) Nuclear isolates from Myd88+/+ or Myd88/ PEMs (L) or human monocyte-derived macrophages (R) were assayed for p65 activation after apoA-I exposure
(20 min, 10 mg/ml) (*p = 0.04; fp = 0.004).
(C–F) Cells were exposed as described and then immunoblotted for the indicated targets. (C) PEMs were cholesterol loaded and cultured in serum-free/0.2%
BSA media, or left unloaded and cultured in complete (10% FBS) media, and then treated with apoA-I (30 mg/ml) or LPS (100 ng/ml, 15 min) in the presence
and absence of polymyxin B (PB). Lysates were then probed for the indicated targets. Lane 4 (LPS in serum-free media) was translocated from original location
on gel for juxtaposition. (D) PEMs were exposed to apoA-I (10 mg/ml) or PGN (10 mg/ml) that had been left untreated or pretreated with Proteinase K (PK). (E) PEMs
were treated with buffer (Bfr), HDL (100 ug/ml), apoA-I (30 mg/ml), or apoE (30 mg/ml) and lysates probed for the indicated targets. (F)Myd88+/+ orMyd88/ PEMs
were exposed to buffer, serum-isolated apoA-I (30 mg/ml), WT recombinant apoA-I (20 mg/ml), or LPS in presence or absence of PB as shown, and then probed for
the indicated targets.
(G) Tirap+/+ and Tirap/ PEMs were treated with apoA-I (10 mg/ml), lysates were immunoblotted for indicated targets, and nuclear isolates were assayed for
p65 activity (20 min exposure; *p = 0.03).
(H) Trif +/+ and Trif /PEMs were treated with apoA-I, lysates immunoblotted for indicated targets, and nuclear isolates assayed for p65 activity (75 min exposure;
*p = 0.02).
(I) C57BL/6 PEMs were stimulated as shown and then assayed for activated (GTP-bound) Cdc42 and Rac. GTPgS-treated lysates (juxtaposed) are shown as
positive control, and total Cdc42 and Rac expression in whole-cell lysate is also shown. Data shown are representative of two independent experiments.
(J) C57BL/6 PEMs were pretreated (4 hr) with C. difficile toxin B (500 ng/ml) or C3 transferase (5 mg/ml), treated with PB, stimulated with apoA-I (10 mg/ml), and
then immunoblotted as shown. Data are results from three independent experiments. All values are means ± SEM. See also Figure S1.
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Figure 2. ApoA-I Signals through TLR2
and TLR4 in the Macrophage
(A and B) WT, Tlr2/, and Tlr4/ PEMs were
treated with apoA-I (10 mg/ml) and lysates immu-
noblotted.
(C) WT, Tlr2/, Tlr4/, or Tlr2/Tlr4 / double
knockout (DKO) PEM nuclear isolates were as-
sayed for p65 activation after apoA-I exposure
(20 min; 10 mg/ml; *p = 0.03 and **p = 0.009
compared to WT). All values are means ± SEM.
(D) Cd14+/+ and Cd14/ PEMs were treated and
immunoblotted as shown (PMA, phorbol myristate
acetate, 32 nM, 15 min; apoA-I, 30 mg/ml).
(E) Abca1/ and Abca1+/+ PEMs were exposed to
apoA-I (10 mg/ml) and lysates probed as shown.
Data are representative of three independent
experiments. See also Figure S2.
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ApoA-I and Innate Immunitydetermined whether TLR4 is itself involved. Unlike LPS signaling,
which, as expected, was abolished in Tlr4/ macrophages (Fig-
ure S2D), apoA-I activated MAPKs in these cells (Figure 2A).
Compared to Tlr4+/+, Tlr4/ macrophages had intact IkBa
degradation but attenuated p38 and JNK activation at 30 and
60 min of exposure (Figure 2A). The marked attenuation of all
signals in Myd88/ and Tirap/ macrophages (Figure 1),
compared with the modest attenuation of MAPKs and intact
degradation of IkBa in Tlr4/ macrophages, suggested that
apoA-I might utilize an additional MyD88- and TIRAP-dependent
TLR, namely TLR2 (O’Neill and Bowie, 2007). Indeed, Tlr2/
macrophages, which, as expected, responded to LPS and
poly(I:C) but not to the TLR2 stimulus Pam3CSK4 (Figure S2E),
had attenuated and delayed activation of p38 and JNK in
response to apoA-I similar to Myd88/ macrophages (Fig-
ure 2B), confirming that apoA-I signaling in the macrophage is
also TLR2 dependent. Consistent with the IkBa findings for
Tlr2/ and Tlr4/ cells, apoA-I-induced activation of p65 was
attenuated in Tlr2/ and in Tlr2/Tlr4/ cells but was intact
in Tlr4/ cells (Figure 2C). CD14 is a coreceptor for TLR2 and
TLR4 stimuli (Kurt-Jones et al., 2000); hence, we questioned
whether it regulates apoA-I signaling. ApoA-I-induced MAPK
activation and IkBa degradation were indeed attenuated in
Cd14/ macrophages (Figure 2D). ATP-binding cassette trans-
porter A1 (ABCA1), a putative receptor for apoA-I, is reported to
lie upstream of apoA-I-induced MAPK activation in fibroblasts
(Nofer et al., 2003; Nofer et al., 2006) and to negatively regulate
LPS signaling in macrophages (Zhu et al., 2008). However, we
found no difference in apoA-I signaling between Abca1+/+ and
Abca1/ macrophages (Figure 2E), indicating that the pathway
we have identified in macrophages is distinct from that reported
in fibroblasts.
ApoA-I Induces MyD88-Dependent Cytokines
and Inflammation
Our finding that apoA-I activates NF-kB was somewhat unex-
pected, given that apoA-I has conventionally been considered
anti-inflammatory (Berbee et al., 2005). To confirm and charac-
terize this proinflammatory response, we analyzed conditioned
media and found that apoA-I induces several NF-kB-dependent
cytokines in murine (Figure 3A) and human (Figure 3B) macro-496 Cell Metabolism 11, 493–502, June 9, 2010 ª2010 Elsevier Inc.phages. Like NF-kB activation, cytokine induction was dramati-
cally dependent upon MyD88, albeit to degrees that varied
among the cytokines (Figure 3A). Microarray analysis confirmed
that a suite of proinflammatory genes is induced by serum-iso-
lated apoA-I with varying dependence upon MyD88, and that
MyD88 regulates >6% of the apoA-I-induced transcriptome
(Table S1). PB abolished LPS-induced TNF-a but did not affect
TNF-a induction by apoA-I; moreover, protease treatment of
apoA-I abolished its ability to induce TNF-a but did not affect
LPS or Pam3CSK4 (Figure S2F). Bacterially expressed WT
apoA-I protein also induced TNF-a in a PB-resistant, MyD88-
dependent fashion (Figure S2G). Given the suite of proinflamma-
tory cytokines induced by apoA-I in vitro, we investigated
whether apoA-I could induce inflammation in vivo by injecting
mice i.p. with serum-isolated apoA-I. Unlike C57BL/6 mice
injected with BSA or saline, neutrophils were recruited to the
peritoneum of apoA-I-injected mice (Figure S3), indicating acute
inflammation. ApoA-I-elicited neutrophil recruitment to the
peritoneum was nearly abolished in Myd88/ and Tlr4/
mice (Figure 4), indicating the dependence of apoA-I-induced
peritonitis upon these two proteins.
TNF-aproduction was also significantly attenuated in Tirap/,
Trif/, Tlr2/, Tlr4 /, and Cd14/ macrophages stimulated
with serum-isolated apoA-I (Figures 5A–5D) with additive
contributions of TLR2 and TLR4 revealed by Tlr2/Tlr4/
macrophages (Figure 5C). By contrast, whereas Abca1/
macrophages were markedly hyperresponsive to both LPS and
Pam3CSK4, inducing elevated levels of TNF-a protein consistent
with prior reports (Zhu et al., 2008), they produced WT levels of
TNF-a in response to apoA-I (Figure 5E).
Reverse Cholesterol Transport Requires MyD88
Given the marked MyD88-dependence of apoA-I signaling, and
previous reports that acute intracellular signals elicited by
apoA-I regulate cholesterol efflux in the fibroblast (Nofer et al.,
2003, 2006), we next investigated whether MyD88 regulates
apoA-I-induced cholesterol efflux from the macrophage. ApoA-I
plays a central role in induction of ABCA1-dependent cholesterol
efflux from cells as the first step of the RCT pathway (Gaus et al.,
2004). Compared to WT, Myd88/ macrophages had elevated
cholesterol efflux into BSA-containing medium; however, unlike
A
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Figure 3. ApoA-I Induces Cytokines
through MyD88-Dependent Mechanism
(A) Myd88+/+ and Myd88 / PEMs were exposed
to buffer or apoA-I (10 mg/ml, 24 hr) and cytokines
quantified in media supernatants by Bio-Plex
assay. *p = 0.02, fp = 0.003, cp = 0.0006,
gp < 0.0001 compared to respective wt. Data is
representative of two experiments with triplicate
samples.
(B) Human monocyte-derived macrophages were
exposed to apoA-I (25 mg/ml, 2 hr), and TNF-a
quantified in media supernatants (ELISA). Data
are results from 3 independent experiments.
*p = 0.0004. All values are means ± SEM. See
also Table S1.
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ApoA-I and Innate ImmunityWT macrophages, Myd88/ cells displayed no apoA-I-induced
cholesterol efflux above BSA background (Figure 6A). These
results, derived from scintillation counting of 3H-cholesterol,
were confirmed by cholesterol mass analysis (Figure S4A).
ApoA-I-induced cholesterol efflux was also significantly
decreased in human macrophages treated with cell-permeant
inhibitors of MyD88 and TIRAP (Figures 6B and 6C). ApoA-I is re-
ported to promote ABCA1-dependent cholesterol efflux in part
through inducing posttranslational upregulation of ABCA1
(Wang et al., 2003). Consistent with a role for MyD88 in this
phenomenon, we found that apoA-I-induced upregulation of
ABCA1 was attenuated in Myd88/ macrophages (Figure 6D).
TNF-a is reported to enhance cholesterol efflux by upregulating
ABCA1 (Gerbod-Giannone et al., 2006). Consistent with this,
TNF-a treatment upregulated ABCA1 protein in peritoneal
macrophages (Figure 6E). Our finding that apoA-I induces
MyD88-dependent TNF-a production (Figure 3A) thus prompted0
1.0
2.0
3.0 ****
ApoA-I
P
M
N
 #
 (x
10
5 )
- + - + - +
WT Myd88 -/- Tlr4 -/-
Figure 4. ApoA-I Elicits TLR4/MyD88-Dependent Inflammation
In Vivo
C57BL/6 (‘‘WT’’), Myd88/, and Tlr4/ mice were injected i.p. with 50 mg
of delipidated BSA (‘‘–’’) or endotoxin-free apoA-I (‘‘+’’). Neutrophils (PMN)
were counted in peritoneal lavage fluid. Data are from two experiments,
n = 8–10 mice per bar in graph. All values are means ± SEM. **p < 0.0001.
See also Figure S3.
Cell Metabolism 11, 493–us to determine whether autocrine sig-
naling from this cytokine might promote
apoA-I-induced cholesterol efflux from
the macrophage. Consistent with this,
apoA-I-induced cholesterol efflux wasindeed attenuated in TNF receptor-deficient macrophages
(Figure 6F). Rho GTPases and JNK reportedly regulate apoA-I-
induced cholesterol efflux in fibroblasts (Nofer et al., 2003). Given
our finding that JNK is activated downstream of MyD88 in a Rho-
dependent fashion (Figures 1I and 1J), we next questioned
whether Rho GTPases regulate macrophage cholesterol efflux.
Like the case for MyD88 deletion (Figure 6, Figure S4A), toxin
B increased cholesterol efflux to BSA but blocked apoA-I-
induced cholesterol efflux above that to BSA carrier (Figure S4B).
Finally, in order to confirm physiological relevance, we adop-
ted a well-established method of measurement of RCT in vivo
(Naik et al., 2006; Navab et al., 2004; Rotllan et al., 2005; Wang
et al., 2007; Zhang et al., 2003). In order to determine whether
macrophage MyD88 regulates RCT in vivo, Myd88+/+ and
Myd88/ macrophages were loaded ex vivo with 3H-choles-
terol/acetylated LDL and then injected i.p. into separate
Myd88+/+ recipients. 3H-cholesterol was then monitored in
plasma and feces to quantify bodily disposal of cholesterol
from the transplanted macrophages. Transport of 3H-cholesterol
into the plasma and feces was significantly reduced from
Myd88/ as compared to Myd88+/+ donor macrophages
(Figure 7), a reduction from WT comparable to that previously
reported for Abca1/ macrophages (Wang et al., 2007). These
data confirm an important role for macrophage MyD88 in RCT
in vivo. Taken together, our study has identified a role for innate
immunity as a physiologic signal in RCT and indicates that innate
immunity and RCT are coupled processes.
DISCUSSION
This report establishes a critical link between the activity of
apoA-I upon innate immunity and its well-established antiathero-
genic function. We report that apoA-I utilizes TLR2, TLR4, CD14,
and the TLR adaptors MyD88, TIRAP, and TRIF to activate
a cascade involving Rho GTPases, MAPKs, and NF-kB, culmi-
nating in induction of cytokines. This response is shared by
lipid-free apoE, suggesting a possible class effect of the
exchangeable amphipathic a-helical apolipoproteins. In support502, June 9, 2010 ª2010 Elsevier Inc. 497
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Figure 5. ApoA-I Induction of TNF-a Is
TIRAP-, TRIF-, TLR2-, TLR4-, and CD14-
Dependent but ABCA1-Independent
(A–D) PEMs from strains shown were stimulated
with apoA-I (30 mg/ml, 20 hr) and TNF-a quantified
in media supernatants (ELISA). Data are results
from three independent experiments. (A) *p =
0.04; (B) *p = 0.001; (C) *p = 0.04 compared to
WT, **p = 0.015 and ***p = 0.003 both compared
to Tlr2/; (D) *p = 0.006.
(E) Abca1+/+ and Abca1/ cholesterol-loaded
PEMs were exposed (6 hr) to apoA-I (30 mg/ml),
Pam3CSK4 (PAM, 100 ng/ml), or LPS (100 ng/ml)
(*p < 0.01, **p < 0.001).
All values are means ± SEM.
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ApoA-I and Innate Immunityof this, apoC-III was recently reported to activate NF-kB in THP-1
cells through interactions with TLR2 (Kawakami et al., 2008). The
response is not triggered, however, by HDL. As HDL, like lipid-
free apoA-I, extracts cellular cholesterol, albeit from different
membrane microdomains (Drobnik et al., 2002), membrane
cholesterol extraction per se does not appear sufficient for
pathway activation. Corroboration of our results with recombi-
nant apoA-I suggests that neither in vivo (e.g., oxidation) nor
ex vivo (i.e., preparative) modifications of the native protein are
likely to explain our results.
Multiple approaches were undertaken to exclude the con-
founding effects of contaminating pathogen-associated molec-A
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TLR4-independent and unaffected by PB, and LPS did not
induce TNF-a under culture conditions in which apoA-I did.
Unlike LPS, PGN, and Pam3CSK4, apoA-I was inactivated by
proteolysis. Unlike apoA-I, both LTA and flagellin are TLR4- and
TRIF-independent, and flagellin and other non-TLR2/TLR4
stimuli are TIRAP-independent (O’Neill and Bowie, 2007). Signif-
icant independent contributions from TLRs other than TLR2 and
TLR4 were excluded by the DKO data. Abca1/ macrophages
were hyperresponsive to LPS and Pam3CSK4 but had normal
responses to apoA-I (Figure 5E) (Zhu et al., 2008). Serum-purified
apoA-I from two sources showed similar results, as did lipid-freeF
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Figure 7. In Vivo Reverse Cholesterol Transport Requires MyD88
RCT of 3H-cholesterol into plasma (A) and feces (B) was assayed at different
time points following i.p. injection of 3H-cholesterol-loaded (1.25 E6 CPMs)
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ApoA-I and Innate ImmunityapoE and bacterially expressed apoA-I, whereas HDL did not
activate the pathway. Most importantly, in vivo RCT, induced
by endogenous apolipoproteins, was also MyD88-dependent.
We cannot exclude low-level endotoxemia in the mouse. Indeed,
endotoxemia occurs in ostensibly healthy humans (Wiedermann
et al., 1999). Hence, apoA-I in vivo may not be naive to PAMPs
and may possibly signal under less purified conditions than we
established in vitro.
It has been proposed that intracellular signals triggered by
apoA-I in fibroblasts, such as JNK activation, regulate ABCA1-
dependent efflux of cellular cholesterol (Gaus et al., 2004; Nofer
et al., 2003). Regulation of ABCA1 expression is an important
mechanism of control of cholesterol efflux to apoA-I. Whereas
apoA-I upregulates ABCA1 in macrophages through intracellular
signals (Wang et al., 2003), LPS impairs cholesterol efflux
through downregulation of ABCA1 (Baranova et al., 2002; Kho-
vidhunkit et al., 2003; McGillicuddy et al., 2009). We propose
that MyD88 promotes apoA-I-induced cholesterol efflux at least
in part through promoting ABCA1 upregulation (Figure 6D). By
contrast, Myd88/ macrophages display enhanced cholesterol
efflux to BSA-containing media (Figure 6A); thus, whether
MyD88 also suppresses ‘‘diffusional’’ cholesterol efflux through
a distinct mechanism is a question worthy of future study.
Notably, we demonstrate that macrophages exposed to apoA-
I in vitro, a model system used by numerous groups to study
cholesterol efflux, express and release multiple cytokines
through a MyD88-dependent mechanism. We propose that
MyD88 may promote apoA-I-induced cholesterol efflux at least
in part through inducing TNF-a, thus allowing for its autocrine
feedback upon the macrophage (Figure 6F). Whether the liver
X receptors regulate apoA-I-induced cholesterol efflux, in part,Cthrough effects on TNF-a induction is an interesting question
worthy of future study.
While acute cellular exposure to lipid-free apoA-I, as per-
formed by us and many others (Gaus et al., 2004; Nofer et al.,
2003, 2006), permits identification of the cell response to
apoA-I, the situation is different in vivo, where macrophages
are tonically exposed to apoA-I, most of it in the form of HDL.
Continuous exposure may possibly induce a form of apoA-I
tolerance, with suppression of the proinflammatory response
to apoA-I, as well as to other raft-dependent stimuli. By analogy,
CDs impair cellular responsiveness to raft-dependent stimuli
including LPS, after acutely inducing proinflammatory signals
(Fessler et al., 2004). This said, our RCT data (Figure 7) do
suggest that MyD88 exerts regulatory tone upon apolipopro-
tein-dependent cholesterol trafficking in vivo. Perhaps more
importantly, although it is accepted that 5%–10% (50–
100 mg/ml) of apoA-I is in lipid-free form in vivo, it has been
shown that in vitro incubation of lipid-free apoA-I with plasma
and injection of lipid-free apoA-I into rodents both lead to very
rapid (<5 min) incorporation of the apolipoprotein into HDL
(Lee et al., 2004). Hence, because of the nature of our approach,
our findings are not inconsistent with those of others that apoA-I
is anti-inflammatory in vivo and in the context of LPS. The lipid-
free population of apoA-I in vivo is determined as a balance
among incorporation into HDL, release from HDL, and lipidation
by ABCA1 to form nascent HDL; these events are proposed to
occur in the subendothelial space (Curtiss et al., 2006). Thus, it
is likely that the proinflammatory potential of apoA-I is veiled
in vivo particularly in the general circulation, whereas low HDL
or conditions modifying HDL composition may partition apoA-I
more toward proinflammatory activity at diseased tissue sites.
Indeed, inflammatory states are associated with release of
lipid-poor apoA-I from HDL (Jahangiri et al., 2009), raising the
possibility that apoA-I may then feed forward to promote further
inflammation. ApoA-I is found within atherosclerotic lesions
(Mucchiano et al., 2001a, 2001b), indeed correlating and coloc-
alizing with inflammatory markers in unstable carotid plaques
from symptomatic patients (Patel et al., 2009).
In summary, we report that apoA-I utilizes MyD88 as a signal
in RCT. These findings add to a growing literature that has
identified overlapping roles for several host proteins in lipid
trafficking and innate immunity, suggesting common origins
for and coupling between metabolism and host defense. This
may not be surprising insofar as microbial and dietary lipids
are coupled in their absorption from the gut and in their systemic
circulation (Cani et al., 2007), and TLR2 and TLR4 stimuli are
generally modified lipids of the bacterial membrane (e.g., LTA,
LPS) that perturb host lipid metabolism (Khovidhunkit et al.,
2004) through interactions with host lipid-binding proteins and
membranes. Macrophages and inflammation are critical
contributors to atherogenesis, but both also have antiathero-
genic activity (Levin et al., 2005; Shi et al., 2000). Thus, while
MyD88-derived inflammation contributes to atherosclerosis by
recruiting monocytes to atheromas (Bjorkbacka et al., 2004b;
Michelsen et al., 2004), macrophage and endothelial MyD88
may have distinct roles. Future investigations will be necessary
to discriminate whether macrophage MyD88 counteracts
atherosclerosis through promoting RCT under permissive
conditions.ell Metabolism 11, 493–502, June 9, 2010 ª2010 Elsevier Inc. 499
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Reagents
The ProteoSpin Endotoxin Removal kit was from Norgen Biotek. The Limulus
amebocyte lysate pyrogent test kit (sensitivity 0.06 EU/ml) was from Cambrex.
PB, PGN, poly(I:C), mbCD (Sigma), human apoE (Calbiochem), human HDL
(Intracel), Pam3CSK4 (InvivoGen), C3 transferase (Cytoskeleton), E. coli
0111:B4 LPS (List Biological), and Proteinase K (Invitrogen) were purchased.
C. difficile toxin B was kindly provided by Dr. Ingo Just. TIRAP and MyD88
inhibitory peptides and control peptide were from Imgenex. Lipid-free human
apoA-I was purchased from two vendors (Calbiochem [R95% purity], Sigma
[>85% purity]) with similar results. Protein purity was confirmed by Sypro
Ruby staining of 10 mg protein resolved by SDS-PAGE.
Mice
Myd88-, Tlr2-, Tlr4-, Trif-, and Tirap-deficient mice have been described
(Horng et al., 2002; Kawai et al., 1999; Takeuchi et al., 1999; Yamamoto
et al., 2003), and were all crossed more than eight generations onto
C57BL/6 background before use. Tlr2-/Tlr4-deficient mice were generated
by crossing Tlr2- and Tlr4-deficient strains. Cd14-deficient mice on a
C57BL/6 background, age- and gender-matched C57BL/6 controls, and
Tnfrsf1a/Tnfrsf1b/ (p55/p75/) mice and B6129SF2/J controls were
purchased from Jackson Laboratories. Macrophage-specific Abca1-deficient
mice (Zhu et al., 2008) were on a mixed B6;129 background and were
compared to littermate controls. All experiments were performed in accor-
dance with the Animal Welfare Act and the U.S. Public Health Service Policy
on Humane Care and Use of Laboratory Animals after review of the protocol
by the National Institute of Environmental Health Sciences (NIEHS) Animal
Care and Use Committee.
Macrophage Harvests
Endotoxin-free reagents and plastics were used in all experiments. For murine
peritoneal macrophage harvests, mice were injected i.p. with Brewer’s thiogly-
collate (2 ml, 4%) and euthanized 96 hr later. The peritoneum was washed
with 10 ml ice cold PBS three times. Cells were spun down (10003 rpm,
6 min, 4C) and washed twice with sterile PBS. Cells were then resuspended
in appropriate media, counted, and plated for experiments. Human peripheral
monocytes were isolated from whole blood by discontinuous plasma Percoll
centrifugation and differentiated to macrophages as described (Haslett
et al., 1985).
Cell Exposures
For apoA-I exposures, peritoneal exudate macrophages were plated at 1–23
106/well in a 12-well plate with DMEM/0.1% FBS and allowed to settle for 2 hr
before adding cholesterol loading media (DMEM/0.1% FBS/2 mg/ml delipi-
dated BSA/10 mg/ml cholesterol). Human macrophages were plated at 5 3
106/well in a 12-well plate with X-vivo media/10% human serum and were
given cholesterol loading media on day 7. The following day, cells were
washed with PBS and media was changed to DMEM/2mg/ml BSA. Polymyxin
B (25 mg/ml) was added 30 min prior to apoA-I in all experiments except
where indicated. LPS and Pam3CSK4 exposures were conducted upon
non-cholesterol-loaded macrophages in complete media (DMEM/10% FBS)
unless otherwise specified. In some experiments as indicated, apoA-I, LPS,
or PGN was pretreated with Proteinase K (0.4 ml enzyme/rxn, 37C overnight,
followed by 80C for 25 min for heat inactivation).
Western Blotting
Cells were lysed and equivalent protein loads resolved by SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were probed with
antibodies against b-actin (#4967; Cell Signaling), phospho-p38 (Thr180/
Tyr182; Cell Signaling), phospho-JNK (Thr183/Tyr185; Cell Signaling), p38
(C-20, sc-535; Santa Cruz), JNK1 (C17, sc-474; Santa Cruz), IkBa (C-21,
sc-371; Santa Cruz), Rac (clone 23A8, Upstate), Cdc42 (P1, sc-98; Santa
Cruz), and ABCA1 (Zhu et al., 2008).
p65 Activation Assay
Nuclear extracts were isolated using the NE-PER kit (Pierce) and equal nuclear
protein aliquots (Bradford assay) analyzed with the TransAM NF-kB p65 kit500 Cell Metabolism 11, 493–502, June 9, 2010 ª2010 Elsevier Inc.(Active Motif) per manufacturer’s conditions. Data is depicted as buffer-
corrected apoA-I-induced p65 binding (i.e., apoA-I-induced p65 activity minus
buffer-induced p65 activity), except where noted.
Rho GTPase Activity Assays
Cdc42 and Rac activity in macrophage lysates (223 106) were quantified with
the Rac Activation Assay Kit (Upstate, Lack Placid, NY) per manufacturer’s
instructions, followed by detection with mouse anti-Rac (Upstate) and rabbit
anti-Cdc42 (Santa Cruz) antibodies.
Cytokine Measurement
Media supernatants were analyzed by either the Bio-Plex multiplex bead assay
(Bio-Rad) or ELISA to mouse or human TNF-a (eBioscience), per manufac-
turer’s specifications.
Intraperitoneal Injection of ApoA-I
Mice were injected i.p. with column-repurified apoA-I (50 mg), delipidated
low-endotoxin BSA (50 mg), or 13 PBS (pH 7.4) or were left untreated. Six
hours later, mice were euthanized, and peritoneal cells were lavaged and
counted. Cytospins were prepared, stained by the Hema 3 Manual Staining
System (Fisher), and leukocyte subpopulations counted.
Cholesterol Efflux Assay
PEMs were plated at 50% confluence in a 24-well plate (2.53 105 cells/well)
in RPMI 1640 with 10% FBS, and human macrophages at 23 106 cells/well
in X-vivo media/10% human serum for 7 days to allow for differentiation. The
following day, medium was changed to RPMI plus 10% lipoprotein deficient
FBS (Intracel). Twenty-four hours later, cells were loaded with 1 mCi/mL [3H]
cholesterol (NEN Life Science Products) in the presence of 50 mg acetylated
LDL (Kalen)/mL in a total volume of 250 ml. The next day, cells were washed
with 13 PBS and were allowed to equilibrate for 4 hr in RPMI/0.2% lipid-free
BSA. Cells were treated in RPMI/0.2% BSA with or without apoA-I in the
presence or absence of 10 mM 22(R)-hydroxycholesterol (LXR agonist; Sigma)
and 1 mM 9 cis-retinoic acid (RXR agonist; Sigma) for 24 hr. The medium was
then collected. Cells were lysed with 200 ml of 0.2N NaOH (RT, 1 hr) and the
lysate was collected; each well was then washed with 50 ml of 0.2N NaOH
and the two fractions combined. Radioactivity was measured (counts per
minute [CPMs]) from the medium and lysates. Cholesterol efflux to BSA or
apoA-I was calculated as the radioactivity (CPMs) recovered in the medium
divided by the sum of radioactivity in medium plus lysate.
Reverse Cholesterol Transport Assay
The following protocol was adapted (Zhang et al., 2003). Myd88+/+ or
Myd88/ PEMs (4 3 107) were plated at 2 3 106/well in a 6-well plate in
RPMI/10% FBS. The following day, wells were washed and loaded with
25 mg/mL acLDL and 5 mCi/well [3H]-cholesterol (60 hr). The cells were then
washed two times with RPMI/0.2% BSA and allowed to equilibrate (4 hr). Cells
were then washed again in RPMI/0.2% BSA, gently scraped with a cell lifter,
spun (10003 rpm, 6 min, 4C) and resuspended in RPMI/0.2% BSA. Radioac-
tivity was measured from each cell prep, and an equal number (1.253 106) of
CPMs was injected into Myd88+/+ recipient mice. Plasma was collected at
24 and 48 hr. A 2 ml sample was measured in a scintillation counter. CPMs/ml
plasma are reported as percent of injected CPMs. Feces were collected at
48 hr, weighed, and soaked in distilled water (1 mL water/100 mg) overnight
at 4C. The next day, an equal volume of ethanol was added and the samples
were homogenized. A 200 ml aliquot of each homogenized sample was
measured on a scintillation counter (Naik et al., 2006).
Cholesterol Mass Analysis
A 100–200 ml volume of medium or cell lysate (including 5a-cholestane as
internal standard) was mixed with 1 ml of 100% ethanol and 100 ml of 50%
KOH, incubated at 65C for 45–60 min, and then allowed to cool to room
temperature. Then, 2.0 ml of hexane and 1.0 ml of water were added and
the sample was vortexed vigorously and centrifuged at 2000 rpm for 5 min.
The upper phase (hexane) was removed, placed in a clean tube, dried down,
brought up in 200 ml of hexane, and analyzed by gas-liquid chromatography
(GLC) (Furbee et al., 2002). Values were normalized to GLC analysis volume.
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Wild-type apoA-I was expressed in E. coli and purified as previously reported
(Lagerstedt et al., 2007; Oda et al., 2003). Recombinant protein was confirmed
by SDS-PAGE, quantified (BCA assay, Pierce), and subjected to LPS removal
(Proteospin, Norgen Biotek), after which it was used for cell exposure at
10 mg/ml (0.06 EU [6 pg]/ml LPS by Limulus assay) or 20 mg/ml in the pres-
ence and absence of polymyxin B (25 mg/ml). The recombinant apoA-I has
been extensively characterized as structurally and functionally comparable
to the native protein (Lagerstedt et al., 2007; Oda et al., 2003).
Microarray Analysis
Total RNA from three independent experiments (four conditions/experi-
ment, Myd88+/+/buffer, Myd88+/+/apoA-I [2 hr; 10 mg/ml]; Myd88//buffer,
Myd88//apoA-I [2 hr]) was extracted from macrophages using the RNeasy
Mini Kit (QIAGEN) and subjected to DNase treatment using QIAGEN’s DNase
set. Gene expression analysis was conducted using Agilent Whole Mouse
Genome (014868) 4x44 multiplex format oligo arrays (Agilent Technologies)
following the Agilent 1-color microarray-based gene expression analysis
protocol. Starting with 500 ng of total RNA, Cy3-labeled cRNA was produced
according to the manufacturer’s protocol. For each sample, 1.65 mg of
Cy3-labeled cRNAs were fragmented and hybridized for 17 hr in a rotating
hybridization oven. Slides were washed and then scanned with an Agilent
Scanner. Data were obtained using the Agilent Feature Extraction Software
(v9.5), using the one-color defaults for all parameters. The Agilent Feature
Extraction Software performed error modeling, adjusting for additive and
multiplicative noise. The resulting data were processed using the Rosetta
Resolver system (version 7.1) (Rosetta Biosoftware, Kirkland, WA). The micro-
array data have been deposited in the NCBI Gene Expression Omnibus and
are accessible through GEO series accession number GSE13772.
Statistics
All data are presented as means ± SEM, and p < 0.05 was considered statis-
tically significant for all assays. Cholesterol efflux was analyzed by two-tailed
t test; the difference between apoA-I and control was further subjected to
a two-way analysis of variance (ANOVA) with genotype and experiment as
the two factors (JMP software).
Plasma samples were analyzed by two-way ANOVA using Prism software
(GraphPad). Cytokine, p65 assays, and PMN counts were analyzed by two-
tailed t test. In the microarray analyses, differentially expressed genes (p <
0.01) were determined by error-weighted ANOVA with multiple test correction
(Bonferroni) using Rosetta Resolver.
Further details on cholesterol mass analysis, apoA-I expression, and micro-
array analysis are available in the Supplemental Information.ACCESSION NUMBERS
The microarray data have been deposited in the NCBI Gene Expression
Omnibus and are accessible through GEO series accession number
GSE13772.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.cmet.2010.04.006.
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